DRL launches Icosapent Ethyl capsules in US
Dr Reddy’s Laboratories on Tuesday announced the launch of Icosapent Ethyl capsules, used to reduce triglyceride (TG) levels in adult patients, in the US market.
image for illustrative purpose
Hyderabad: Dr Reddy's Laboratories on Tuesday announced the launch of Icosapent Ethyl capsules, used to reduce triglyceride (TG) levels in adult patients, in the US market.
The company has launched Icosapent Ethyl Capsules in 1 gram strength after approval by the US Food and Drug Administration (USFDA), Dr Reddy's said in a regulatory filing. Dr Reddy's Icosapent Ethyl is available in 1 gram capsules in bottle count size of 120's count.
Icosapent Ethyl capsules, 1 gram, is approved as an adjunct to diet to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia. Shares of Dr Reddy's were trading 0.14 per cent lower at Rs 5,272.05 apiece on the BSE.
